Aims To characterize the pharmacokinetics and metabolism of oral midazolam in 15 preterm
infants. Methods After an oral dose (0.1 mg kg− 1), blood was drawn up to 24 h after …

Background Midazolam, a benzodiazepine, is finding expanded use in neonatal intensive
care units. We studied the pharmacokinetics and metabolism of midazolam after a single …

Objective To describe the pharmacokinetics of midazolam, a water‐soluble benzodiazepine
with a short half‐life, in critically ill neonates. Hypothesis Midazolam clearance is reduced in …

A simple, selective high‐performance liquid chromatographic method with ultraviolet
detection at 220nm is described for quantitation of midazolam and its primary metabolite 1 …

Purpose In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam
(OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently …

Objective The aim of this study was to evaluate the pharmacodynamics and safety of
midazolam after intravenous infusion or oral administration in preterm infants. Methods] …

Midazolam is a benzodiazepine with rapid onset of action and short duration of effect. In
healthy neonates the half‐life (t1/2) and the clearance (Cl) are 3.3‐fold longer and 3.7‐fold …

Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and
children. An IV bolus of midazolam 0.2 mg· kg− 1 was administered to 10 critically ill …

A serum concentration profile study on midazolam in children was done. Fifty six children
aged 3–10 years took part. The routes investigated were intravenous, intramuscular, rectal …

To predict first‐pass and systemic cytochrome P450 (CYP) 3A‐mediated metabolism of
midazolam in preterm neonates, a physiological population pharmacokinetic model was …